From the clinicoeconomic viewpoints the treatment of community-acquired pneumonia in patients without risk factors under hospital conditions with aminopenicillins was more appropriate, whereas for the treatment of patients with risk factors the following scheme of antibiotic therapy was advantageous: a beta-lactam (cefotaxime/ceftriaxone) in combination with a macrolide (azithromycin). The recommended therapy provided statistically lower percentage of negative pneumonia processes and decreased the treatment expenditures.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
community-acquired pneumonia
8
patients risk
8
risk factors
8
[antibiotic therapy
4
therapy mild
4
mild community-acquired
4
pneumonia inpatients]
4
inpatients] clinicoeconomic
4
clinicoeconomic viewpoints
4
viewpoints treatment
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!